Cancer Cachexia

Slide 1 · Cancer Cachexia

A systemic metabolic complication of malignancy

Mechanisms • tissue atrophy • clinical consequences

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Define cachexia as a hypercatabolic syndrome centered on skeletal-muscle loss.

Trace inflammatory signals to muscle-protein degradation and clinical weakness.

Explain GDF-15/GFRAL–associated appetite suppression and limits of evidence.

Distinguish cachexia from decreased intake alone and interpret clinical scenarios.

Slide 3 · Why a systemic tumor complication matters

Mechanism / evidence

Local tumor effects depend on location: Obstruction, tissue injury, bleeding.

Cancer can also affect distant tissues without directly invading them.

Clinical / interpretation

Cachexia is a major systemic syndrome.

Its defining tissue injury is loss of skeletal-muscle mass.

Slide 4 · Core definition: Beyond inadequate intake

Cancer-associated hypercatabolism

Skeletal-muscle loss

Functional decline

Loss of fat may accompany the loss of muscle; Reduced food intake alone does not account for the syndrome.

Slide 5 · Muscle loss is the indispensable feature

Mechanism / evidence

Progressive depletion of skeletal-muscle mass defines the syndrome.

Myofibrillar proteins are substrates for accelerated proteolysis.

Clinical / interpretation

Adipose-tissue depletion can coexist.

Fat loss is not required by the Robbins definition.

Slide 6 · Cachexia is not simply anorexia

Anorexia

Reduced desire to eat.

Can contribute to weight loss.

Describes intake behavior.

Cancer cachexia

Muscle-wasting hypercatabolic state.

May include anorexia.

Not explained by intake reduction alone.

Slide 7 · Starvation versus inflammatory wasting

Inadequate nutrient supply

Primary limitation: Intake or absorption.

Nutrient deprivation leads to tissue consumption.

Malnutrition may occur without cancer.

Cancer-associated hypercatabolism

Host- and tumor-related signals contribute.

Muscle proteolysis can continue despite adequate intake.

Inflammation-related metabolism is central.

Slide 8 · Hypercatabolism explains disproportionate wasting

The syndrome is defined by net tissue breakdown rather than weight loss alone.

Inflammatory mediators act on the metabolism of skeletal muscle.

Structural muscle-protein degradation compromises contractile tissue.

Anorexia may compound—but does not fully explain—the deficit.

Slide 9 · How frequently does cachexia occur?

~50%

Of patients with cancer, according to the Robbins textbook estimate.

A broad textbook estimate—not a prevalence for every tumor type or stage.

Slide 10 · Clinical settings emphasized by Robbins

The syndrome is especially associated with advanced malignancy.

Advanced gastrointestinal cancers are highlighted.

Pancreatic and lung cancers are also commonly associated.

Frequency varies by tumor setting; Robbins does not provide subtype-specific estimates here.

Slide 11 · Why tumor stage matters

Mechanism / evidence

Advanced cancer is a characteristic clinical setting.

Tumor-associated inflammation may be systemic.

Clinical / interpretation

The presence of cachexia signals clinically meaningful host involvement.

The source does not define a tumor stage threshold for diagnosis.

Slide 12 · Mortality burden described

~30%

Of cancer deaths are attributed to cachexia.

This is the textbook’s summary estimate; It is not a patient-specific risk or a trial result.

Slide 13 · The clinical phenotype has several domains

Mechanism / evidence

Body composition: Muscle atrophy; Often conspicuous weight loss.

Nutrition: Anorexia; Fat loss may occur.

Clinical / interpretation

Function: Fatigue and profound weakness.

Additional findings: Anemia and edema.

Slide 14 · From myosin loss to weakness

Myofibrillar protein degradation

Reduced contractile apparatus

Muscle weakness and fatigue

Skeletal-muscle atrophy links molecular proteolysis to the clinical phenotype.

Slide 15 · Weight loss is an important clue—not the definition

Extreme weight loss is characteristic of severe cancer cachexia.

Changes in fat and fluid may alter apparent body weight.

Muscle mass and function remain central to the pathologic process.

Do not infer the absence of cachexia from weight alone.

Slide 16 · Anorexia and catabolism can act together

Mechanism / evidence

Appetite suppression reduces dietary intake.

GDF-15/GFRAL is one proposed appetite pathway.

Clinical / interpretation

Inflammatory signals promote skeletal-muscle proteolysis.

Thus two separable processes can worsen tissue depletion.

Slide 17 · Fatigue and weakness: A mechanistic reading

Muscle atrophy reduces the contractile reserve of skeletal muscle.

Anemia is among the accompanying systemic findings.

Fatigue is therefore clinically important but not mechanistically specific.

The source does not assign a quantitative contribution to each mechanism.

Slide 18 · Anemia and edema: Associated findings

Anemia

Listed among characteristic manifestations.

Can aggravate fatigue and reduced tolerance of exertion.

Multiple causes may coexist in an individual with cancer.

Edema

Also listed among characteristic manifestations.

Fluid retention may obscure change in body weight.

It is not itself the defining tissue-loss process.

Slide 19 · Why respiratory-muscle loss is dangerous

Skeletal muscle atrophy

Diaphragm / respiratory muscles affected

Potential fatal respiratory compromise

Respiratory-muscle atrophy as a major explanation for cachexia-related mortality.

Slide 20 · The diaphragm is skeletal muscle

The diaphragm and accessory respiratory muscles share vulnerability to muscle atrophy.

Marked loss of contractile tissue can diminish respiratory muscle capacity.

Cachexia-associated deaths particularly to respiratory-muscle atrophy.

This is a systemic consequence—not direct tumor infiltration of the diaphragm.

Slide 21 · Teaching vignette: Wasting despite eating

Hypothetical teaching case

Hypothetical patient with advanced lung cancer, declining muscle bulk, fatigue, and weight loss. Family reports that reduced food intake seems too modest to explain the wasting.

Which feature points toward cancer cachexia rather than low intake alone?

Disproportionate skeletal-muscle loss in a hypercatabolic cancer setting.

Slide 22 · What the bedside phenotype cannot prove

Weight loss and anorexia do not identify which signaling pathway is active.

Anemia, edema, and weakness are not individually specific to cachexia.

The molecular explanation is supported by experimental and clinical evidence—not a single routine marker in the excerpt.

Avoid equating any one symptom with a molecular diagnosis.

Slide 23 · The inflammatory model of cachexia

Tumor and host inflammatory response

Cytokine signaling

Muscle-protein degradation

Skeletal-muscle atrophy

The source places TNF, IL-1, and IL-6 among candidate mediators rather than a fully resolved single pathway.

Slide 24 · Two interacting biological compartments

Mechanism / evidence

Tumor and its microenvironment can provoke chronic inflammation.

Host immune cells generate inflammatory mediators.

Clinical / interpretation

Remote skeletal muscle is a target tissue.

Signals may change protein turnover even without tumor invasion of muscle.

Slide 25 · Inflammatory mediators emphasized

Tumor necrosis factor (TNF).

Interleukin-1 (IL-1).

Interleukin-6 (IL-6).

All three are implicated; The source explicitly notes uncertainty about precise causes.

Slide 26 · TNF connects inflammation and metabolism

Mechanism / evidence

TNF has systemic actions during inflammatory responses.

It can promote lipid and protein mobilization.

Clinical / interpretation

Sustained TNF can suppress appetite.

These effects make TNF biologically plausible in cachexia—but do not establish sufficiency in patients.

Slide 27 · IL-1: Experimental evidence

Mechanism / evidence

Administration to mice can reproduce cachexia-like wasting.

IL-1 participates in systemic inflammatory reactions.

Clinical / interpretation

Robbins implicates IL-1 in the inflammatory component.

A unique IL-1–only clinical mechanism is not established in the excerpt.

Slide 28 · IL-6: Systemic inflammation and wasting

Mechanism / evidence

IL-6 is among the mediators highlighted in cancer cachexia.

It also participates in systemic inflammatory responses.

Clinical / interpretation

Administered IL-6 induces cachexia in mouse experiments.

Its isolated causal contribution in an individual patient remains unresolved.

Slide 29 · Cytokine administration: Evidence for plausibility

Experiment

Administer TNF, IL-1 or IL-6 to mice.

Observation

Each can induce cachexia in the animal model.

Interpretation

A cytokine can drive wasting under experimental conditions.

Limit

This does not establish a single-cytokine cure in patients.

Slide 30 · TNF-receptor knockout: Genetic evidence

Model

Tumor-bearing mice lacking TNF-receptor signaling.

Observation

Protection from cachexia in this model.

Inference

TNF signaling matters mechanistically.

Limit

Mouse protection is not proof of clinical therapeutic efficacy.

Slide 31 · Human cytokine studies: Association

Observation

Patients with cancer cachexia have elevated inflammatory cytokines.

Evidence type

Clinical association, not intervention.

Supports

A role for systemic inflammation in human cachexia.

Does not prove

That one cytokine independently causes each case.

Slide 32 · Experimental manipulation versus association

Experimental models

Cytokine delivery induces wasting in mice.

TNF-receptor knockout confers protection.

Stronger leverage over causal pathways in that model.

Human observational studies

Higher cytokine levels accompany cachexia.

Direct association with a human phenotype.

Potential confounding and reverse causation remain.

Slide 33 · Why the evidence does not identify one cause

Multiple cytokines reproduce wasting in experimental systems.

Clinical patients differ from controlled animal models.

Elevated cytokine levels are associated with—but not by themselves proof of—causality.

The negative TNF-targeting therapeutic experience argues against a single-factor account.

Slide 34 · Direct cytokine effects on skeletal muscle

Inflammatory cytokine signal

Ubiquitination of muscle proteins

Proteasome-mediated degradation

Reduced muscle mass

Robbins specifically names myosin heavy chain among degraded structural proteins.

Slide 35 · Myosin heavy chain is a key substrate

Mechanism / evidence

Myosin is a major structural component of the contractile apparatus.

Its heavy chain is named in the cachexia mechanism.

Clinical / interpretation

Increased degradation diminishes skeletal-muscle protein content.

Contractile function is affected as atrophy advances.

Slide 36 · Protein tagging: Ubiquitination

Muscle protein targeted

Ubiquitin attached

Tagged protein selected for breakdown

Chapter 2 identifies ubiquitin ligases as enzymes that attach ubiquitin to target proteins.

Slide 37 · Proteasomes execute protein breakdown

Ubiquitinated substrate

Proteasome

Peptide / protein degradation

The ubiquitin-proteasome pathway is a major route of cellular protein turnover.

Slide 38 · Integrated myofibrillar degradation pathway

Inflammatory mediator

Skeletal-muscle signaling

Myosin ubiquitination

Proteasomal proteolysis

Muscle atrophy

Directed schematic of the pathway; Intermediate signaling components are intentionally unnamed.

Slide 39 · Atrophy reflects altered protein balance

Reduced synthesis

Lower trophic signaling can reduce nutrient uptake and mRNA translation.

Contributes to declining cell protein content.

Increased degradation

Ubiquitin-proteasome pathway increases protein destruction.

Explicitly implicated in cancer-related cachexia.

Slide 40 · Cellular appearance of atrophic muscle

Atrophic cells are smaller and have less cytoplasmic machinery.

Fewer myofilaments and mitochondria.

Reduced rough endoplasmic reticulum is also noted.

These are general changes of atrophy, not a diagnostic biopsy pattern unique to cancer.

Slide 41 · Atrophy initially favors survival over function

Mechanism / evidence

Cell size and organelle content decline.

Lower cellular metabolic demands may help adaptation.

Clinical / interpretation

Functional capacity diminishes early.

Marked loss of muscle mass can later produce severe systemic consequences.

Slide 42 · Where does autophagy fit?

Mechanism / evidence

In many forms of atrophy, autophagic vacuoles increase.

Autophagy can remove intracellular components.

Clinical / interpretation

Robbins directly emphasizes proteasomal breakdown in cancer cachexia.

Do not conflate general autophagic atrophy with a proven cachexia-specific dominant mechanism.

Slide 43 · A metabolic bridge: Inflammation-related malnutrition

Inflammatory mediators

Increased resting energy expenditure

Skeletal-muscle protein catabolism

Amino acids for glucose synthesis

General pathway described under inflammation-related malnutrition; Robbins suggests overlap with cancer cachexia.

Slide 44 · Adequate dietary protein may not prevent catabolism

Intake-related model

Nutrient shortage constrains available substrate.

Improved intake addresses the initiating deficit.

Inflammation-related model

Inflammatory catabolism can persist despite adequate protein intake.

The pathologic driver is more than substrate deficiency.

Slide 45 · Two converging routes to tissue depletion

Reduced appetite / intake

Inflammation-driven proteolysis

Skeletal-muscle protein loss

This schematic shows two contributing inputs; Do not infer their relative magnitude in any patient.

Slide 46 · GDF-15 adds a neurohumoral pathway

Mechanism / evidence

Growth differentiation factor-15 (GDF-15) is a protein mediator.

Secretion from tumor cells and macrophages.

Clinical / interpretation

GDF-15 acts via GFRAL in the brainstem.

An important reported consequence is appetite suppression.

Slide 47 · GDF-15/GFRAL appetite circuit

Tumor cells / macrophages

GDF-15

GFRAL in brainstem

Suppressed appetite

Proposed pathway as. Exact central circuitry is not defined in the excerpt.

Slide 48 · Origin of the GDF-15 signal

Mechanism / evidence

Tumor cells can produce GDF-15.

Macrophages are another described source.

Clinical / interpretation

Both cellular sources can contribute to a systemic signal.

Their relative contributions are not specified by Robbins.

Slide 49 · The GFRAL receptor localizes the appetite effect

Mechanism / evidence

GFRAL is identified as a receptor in the brainstem.

Binding of GDF-15 is linked to appetite suppression.

Clinical / interpretation

The source does not map downstream neuronal pathways.

Do not add undocumented brain nuclei or signaling intermediates.

Slide 50 · Two mechanism branches with different targets

Inflammatory / muscle axis

TNF, IL-1, IL-6 are implicated.

Muscle protein ubiquitination and proteolysis.

Prominent consequence: Muscle atrophy.

GDF-15 / appetite axis

GDF-15 binds brainstem GFRAL.

Suppression of appetite.

Consequence: Reduced food intake may contribute.

Slide 51 · GDF-15/GFRAL inhibition in animals

Intervention

Block GDF-15 or its receptor, GFRAL.

Model

Animals with cancer-associated wasting.

Observation

Cancer cachexia is blocked in reported animal models.

Interpretation

Supports the functional relevance of this pathway.

Slide 52 · Early clinical anti–GDF-15 observations

Setting

Early clinical trials in cancer patients.

Intervention

Inhibitors of GDF-15.

Reported finding

Suppression of cachexia.

Important qualification

Mechanisms and long-term clinical implications remain incompletely understood.

Slide 53 · The GDF-15 hypothesis remains incomplete

GDF-15 as one contributing factor—not the whole cause.

Its described receptor-mediated effect is appetite suppression.

Animal studies and early clinical trials provide encouraging signals.

The mechanism of action remains incompletely understood.

Slide 54 · Why blocking TNF did not reverse cachexia

Biology

TNF can induce wasting and is supported by mouse genetics.

Clinical test

Therapies directed against TNF alone.

Outcome

Not effective in reversing human cancer cachexia.

Lesson

Mechanistic plausibility does not guarantee a successful therapy.

Slide 55 · Interventions: Distinguish evidence levels

Single-cytokine targeting

Experimental causal support is substantial.

Anti-TNF clinical reversal was unsuccessful.

No simple single-cytokine treatment inference.

GDF-15 pathway inhibition

Animal blockade was effective in reported models.

Early clinical signals suggest suppression of cachexia.

Not equivalent to established long-term outcomes.

Slide 56 · Multifactorial disease: An integrated model

Tumor and host factors

Muscle proteolysis + reduced intake

Skeletal-muscle loss

Debility / mortality

Model summarizes the textbook; Not a validated quantitative predictive algorithm.

Slide 57 · Inflammatory cachexia also occurs without cancer

Cancer cachexia

Malignancy is the clinical driver.

Common with advanced GI, pancreatic, lung cancers.

Inflammation plus other tumor/host mediators.

Noncancer cachectic states

Chronic disseminated infections and AIDS are examples.

Inflammatory cytokines may also contribute.

Similar phenotype does not establish malignancy.

Slide 58 · How to interpret a wasting phenotype

First establish whether skeletal-muscle wasting is present.

Consider low intake, malabsorption, and inflammation-related mechanisms.

Interpret anorexia, anemia, and edema as associated findings—not standalone proof.

In a patient with malignancy, consider the hypercatabolic process emphasized by Robbins.

Slide 59 · Three distinct sources of impairment in cancer

Local disease

Direct tumor pressure, invasion, obstruction or tissue destruction.

Paraneoplastic phenomena

Distant syndromes not explained by tumor site or native hormones.

Cancer cachexia

Systemic muscle-wasting and appetite/metabolic disturbances.

Slide 60 · Teaching vignette: Edema masks tissue loss

Hypothetical teaching case

Hypothetical patient with pancreatic cancer has progressive proximal-muscle wasting, reduced strength, ankle swelling, and limited change on the scale.

Why might recorded weight be an incomplete descriptor of this syndrome?

Edema can coexist with major skeletal-muscle atrophy; Muscle loss is the defining feature.

Slide 61 · Teaching vignette: A negative trial

Hypothetical teaching case

A cytokine reproduces wasting in mice, and its receptor knockout protects tumor-bearing animals. Yet patients do not recover after that cytokine is blocked.

Which scientific conclusion is most defensible?

The pathway contributes to an experimental mechanism; Human cachexia is multifactorial.

Slide 62 · Teaching vignette: Appetite signaling

Hypothetical teaching case

A tumor-associated protein produced by malignant cells and macrophages binds a brainstem receptor and suppresses appetite.

Name the mediator–receptor pair and its principal described effect.

GDF-15 → GFRAL; Appetite suppression.

Slide 63 · Evidence hierarchy and what remains unknown

Mechanism / evidence

Established in textbook: Muscle loss, clinical syndrome, inflammatory association, proteasomal degradation.

Strong mechanistic clues: Mouse cytokine experiments and TNF-receptor knockout.

Clinical / interpretation

Emerging: Anti–GDF-15 early clinical observations.

Unresolved: Precise combination of factors and detailed GDF-15 mechanism.

Slide 64 · High-yield synthesis

Cancer cachexia is hypercatabolic skeletal-muscle loss not explained by inadequate intake.

TNF, IL-1 and IL-6 are implicated in muscle protein degradation via the ubiquitin–proteasome pathway.

GDF-15 signals through brainstem GFRAL to suppress appetite.

Multifactorial biology explains why single-mediator therapeutic approaches may fail.

Slide 65 · References and source boundaries

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th ed. 2026. Chapter 7: Neoplasia, pp. 293–294.

Supporting textbook context: Chapter 2 (Atrophy); Chapter 3 (systemic cytokine effects); Chapter 9 (inflammation-related malnutrition).

Figures in this lecture are original editable schematics; no clinical images or quantitative trial plots were recreated.

No current guideline, drug approval status, or external diagnostic threshold has been added.